158 related articles for article (PubMed ID: 18553158)
1. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
[TBL] [Abstract][Full Text] [Related]
2. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
3. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
Ely SA; Knowles DM
Am J Pathol; 2002 Apr; 160(4):1293-9. PubMed ID: 11943714
[TBL] [Abstract][Full Text] [Related]
5. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma.
Harrington AM; Hari P; Kroft SH
Am J Clin Pathol; 2009 Jul; 132(1):60-6. PubMed ID: 19864234
[TBL] [Abstract][Full Text] [Related]
6. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
7. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Involvement in Plasma Cell Myeloma.
Panse G; Subtil A; McNiff JM; Glusac EJ; Ko CJ; Galan A; Myung P; Xu ML
Am J Clin Pathol; 2021 Jan; 155(1):106-116. PubMed ID: 32885235
[TBL] [Abstract][Full Text] [Related]
9. [Morphological diagnosis of plasmocytic myeloma in trephine biopsy (histological and immunohistochemical criteria)].
Baĭkov VV
Arkh Patol; 2007; 69(2):50-2. PubMed ID: 17642196
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow trephine biopsy findings in myeloma with small-lymphoid cells and CCND1 translocation.
Abdalla S; May PC; Garimberti E; Naresh KN
Am J Hematol; 2011 Dec; 86(12):1038. PubMed ID: 21898528
[No Abstract] [Full Text] [Related]
12. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
13. A new phenotypic classification of bone marrow plasmacytosis.
Kawano MM; Mihara K; Tsujimoto T; Huang N; Kuramoto A
Int J Hematol; 1995 Jun; 61(4):179-88. PubMed ID: 8547606
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
15. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities.
Salama ME; Du S; Efimova O; Heikal NM; Wendlandt E; Toydemir RM; South S; Perkins SL; Hussong JW; Zhan F
Leuk Lymphoma; 2015 Feb; 56(2):426-33. PubMed ID: 24913506
[TBL] [Abstract][Full Text] [Related]
16. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.
Pellat-Deceunynck C; Barillé S; Jego G; Puthier D; Robillard N; Pineau D; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Leukemia; 1998 Dec; 12(12):1977-82. PubMed ID: 9844928
[TBL] [Abstract][Full Text] [Related]
17. Immunohistological analysis in diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD38-positive plasma cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Nishiwaki U; Masuda Y; Hiraoka N; Takayama A; Nishimura Y; Tsuji M; Hanafusa T
Hematology; 2012 Nov; 17(6):317-20. PubMed ID: 23168070
[TBL] [Abstract][Full Text] [Related]
18. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
Rasmussen T; Kuehl M; Lodahl M; Johnsen HE; Dahl IM
Blood; 2005 Jan; 105(1):317-23. PubMed ID: 15339850
[TBL] [Abstract][Full Text] [Related]
19. The neural cell adhesion molecule NCAM in multiple myeloma.
Kaiser U; Auerbach B; Oldenburg M
Leuk Lymphoma; 1996 Feb; 20(5-6):389-95. PubMed ID: 8833394
[TBL] [Abstract][Full Text] [Related]
20. The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma.
Warnnissorn AN; Treetipsatit J; Limvorapitak W
Hematology; 2020 Dec; 25(1):292-298. PubMed ID: 32772824
[No Abstract] [Full Text] [Related]
[Next] [New Search]
